Glicophos
Ask a doctor about a prescription for Glicophos
How to use Glicophos
Leaflet attached to the packaging: information for the user
Warning! Keep the leaflet! Information on the immediate packaging in a foreign language.
Glycophos, 216 mg/ml, concentrate for solution for infusion
Sodium glycerophosphate
You should carefully read the contents of the leaflet before using the medicine, as it contains important information for the patient.
- You should keep this leaflet, so that you can read it again if you need to.
- If you have any doubts, you should consult a doctor, pharmacist, or nurse.
- This medicine has been prescribed specifically for you. Do not pass it on to others. The medicine may harm another person, even if their symptoms are the same.
- If the patient experiences any side effects, including any side effects not listed in this leaflet, they should tell their doctor, pharmacist, or nurse. See section 4.
Table of contents of the leaflet
- 1. What is Glycophos and what is it used for
- 2. Important information before using Glycophos
- 3. How to use Glycophos
- 4. Possible side effects
- 5. How to store Glycophos
- 6. Contents of the packaging and other information
1. What is Glycophos and what is it used for
Glycophos is a medicine that contains glycerophosphate, which is important for fat metabolism in the body.
The medicine is administered by intravenous infusion.
Indications for use:
Glycophos is indicated for use in adult patients and infants as a supplement to phosphate requirements in parenteral nutrition.
2. Important information before using Glycophos
When not to use Glycophos
Do not use the medicine:
- if the patient is allergic to the active substance or to any of the other ingredients of this medicine (listed in section 6);
- if the patient is dehydrated (has lost a lot of fluids or blood);
- if the patient has hypernatremia (elevated sodium levels in the blood);
- if the patient has hyperphosphatemia (elevated phosphate levels in the blood);
- if the patient has severe renal failure;
- if the patient is in shock (a life-threatening condition caused by sudden lack of oxygen in the body).
Warnings and precautions
Before starting to use Glycophos, you should discuss it with your doctor or nurse.
- The medicine should be administered with caution if the patient has kidney function disorders.
- In patients who are using Glycophos, the doctor will order regular blood phosphate level tests.
Glycophos and other medicines
You should tell your doctor or pharmacist about all the medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
No interactions between Glycophos and other medicines have been found, but when used concomitantly with carbohydrates (sugars), a decrease in blood phosphate levels may be observed.
Pregnancy and breastfeeding
If the patient is pregnant or breastfeeding, thinks she may be pregnant, or plans to have a child, she should consult her doctor or pharmacist before using this medicine.
The doctor will decide whether to use Glycophos in pregnant or breastfeeding women.
Driving and using machines
Glycophos does not affect the ability to drive or use machines.
Glycophos contains sodium
1 ml of the medicine contains 2 mmol of sodium. This should be taken into account in patients with reduced kidney function and in patients controlling their sodium intake.
3. How to use Glycophos
This medicine is administered only by medical personnel. The medicine must not be used by itself.
In case of doubts, you should consult a doctor.
The dosage is determined by the doctor individually for each patient, depending on age, body weight, and phosphate requirements.
The duration of intravenous infusion should not be less than 8 hours.
Using a higher dose of Glycophos than recommended
If a higher dose of the medicine than recommended is used, you should immediately tell your doctor or nurse.
No symptoms of overdose have been found.
In case of any further doubts related to the use of this medicine, you should consult your doctor or nurse.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
No side effects due to glycerophosphate have been found.
Reporting side effects
If any side effects occur, including any side effects not listed in the leaflet, you should tell your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl.
Reporting side effects will help to gather more information on the safety of the medicine.
5. How to store Glycophos
The medicine should be stored out of sight and reach of children.
Store in a temperature below 25°C. Do not freeze.
Any unused contents of an opened vial or ampoule should be discarded, and not stored for further use.
Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the month stated.
Medicines should not be disposed of via wastewater or household waste containers. You should ask your pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
6. Contents of the packaging and other information
What Glycophos contains
- The active substance of the medicine is sodium glycerophosphate.
1 ml of the medicine contains:
216 mg of sodium glycerophosphate in the form of 306.1 mg of hydrated sodium glycerophosphate, which is equivalent to 1 mmol of phosphate and 2 mmol of sodium.
- The other ingredients are: hydrochloric acid, water for injections.
The osmolality of the medicine is 2760 mOsm/kg of water, pH 7.4.
What Glycophos looks like and what the packaging contains
The medicine is a concentrate for solution for infusion.
Packaging size:
- Polypropylene vials containing 20 ml of concentrate for solution for infusion, packed in cartons of 10.
- Polypropylene ampoules containing 20 ml of concentrate for solution for infusion, packed in cartons of 10 or 20.
For more detailed information, you should contact the marketing authorization holder or parallel importer.
Marketing authorization holder in Greece, the country of export:
Fresenius Kabi Hellas A.E.
- L. Kifisias 64A, 151 25 Marousi, Attica, Greece
Manufacturer:
Fresenius Kabi Norge AS
Svinesundsveien 80
NO-1788 Halden, Norway
Parallel importer:
InPharm Sp. z o.o.
ul. Strumykowa 28/11
03-138 Warsaw
Repackaged by:
InPharm Sp. z o.o. Services sp. k.
ul. Chełmżyńska 249
04-458 Warsaw
Marketing authorization number in Greece, the country of export:61149/4-12-2007
69035/18-07-2022
Parallel import authorization number: 77/24
Date of leaflet approval: 27.02.2024
Information intended only for healthcare professionals:
Dosage and administration
Glycophos must not be administered undiluted.
Dosage
Adult patients:
Individual dosing is recommended.
The recommended daily dose of phosphate during parenteral nutrition is usually 10 to 20 mmol. This can be achieved by using 10 to 20 ml of Glycophos added to the infusion solution or to the nutritional mixture, whose compatibility has been confirmed.
Infants:
Individual dosing is recommended.
The recommended dose for infants and newborns is 1.0 to 1.5 mmol/kg body weight/day.
Administration method
Intravenous infusion. The duration of the infusion should not be less than 8 hours.
Overdose
No side effects due to overdose have been found. Most patients requiring parenteral nutrition show increased ability to absorb glycerophosphate.
Preparation of the medicine for use
Other medicines should be added under aseptic conditions.
Incompatibilities
Glycophos can be added or mixed only with medicines whose compatibility has been established.
Medicines to be added
Up to 1000 ml of Vamin 14 Electrolyte-Free, Vamin 18 Electrolyte-Free, or Vaminolact, no more than 120 ml of Glycophos and 48 mmol of calcium (in the form of CaCl) can be added.
Up to 1000 ml of glucose 50 mg/ml, no more than 10 ml of Glycophos and 10 mmol of calcium (in the form of CaCl) can be added.
Up to 1000 ml of glucose 200 mg/ml, no more than 20 ml of Glycophos and 20 mmol of calcium (in the form of CaCl) can be added.
Up to 1000 ml of glucose 500 mg/ml, no more than 60 ml of Glycophos and 24 mmol of calcium (in the form of CaCl) can be added.
Stability
When adding other medicines to the infusion solution, the infusion should be completed within 24 hours of preparation; this will prevent microbiological contamination.
Any unused contents of an opened vial or ampoule should be discarded, and not stored for further use.
Storage conditions
Store in a temperature below 25°C. Do not freeze.
Disposal of unused medicine
Any unused medicine or waste material should be disposed of in accordance with local regulations.
- Country of registration
- Active substance
- Prescription requiredNo
- Marketing authorisation holder (MAH)Fresenius Kabi Hellas A.E.
- This information is for reference only and does not constitute medical advice. Always consult a licensed doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to GlicophosDosage form: Concentrate, -Active substance: electrolytes in combination with other drugsManufacturer: Fresenius Kabi Norge ASPrescription not requiredDosage form: Concentrate, (170.1 mg + 133.5 mg + 14 mg)/mlActive substance: electrolytes in combination with other drugsPrescription not requiredDosage form: Solution, 1 g/10 mlActive substance: calcium chlorideManufacturer: Demo S.A.Prescription required
Alternatives to Glicophos in other countries
The best alternatives with the same active ingredient and therapeutic effect.
Alternative to Glicophos in Spain
Online doctors for Glicophos
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for Glicophos – subject to medical assessment and local rules.
Get updates and exclusive offers
Be the first to know about new services, marketplace updates, and subscriber-only promos.
